Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Ultragenyx Pharmaceutical's net current asset value per share for the quarter that ended in Mar. 2026 was MXN-160.49.
The historical rank and industry rank for Ultragenyx Pharmaceutical's Net Current Asset Value or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Ultragenyx Pharmaceutical was 116.98. The lowest was 5.12. And the median was 8.30.
MEX:RARE's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 4.91 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Ultragenyx Pharmaceutical (MEX:RARE) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Ultragenyx Pharmaceutical Net Current Asset Value Related Terms
Ultragenyx Pharmaceutical Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Ultragenyx Pharmaceutical's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ultragenyx Pharmaceutical Net Current Asset Value Chart
MEX:RARE vs VERA, IRON, QURE: Net Current Asset Value Comparison
For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ultragenyx Pharmaceutical Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Ultragenyx Pharmaceutical's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of MXN-160.49 mean?
Ultragenyx Pharmaceutical (MEX:RARE) has a Net Current Asset Value of MXN-160.49 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Ultragenyx Pharmaceutical and its competitors. Over the past decade, Ultragenyx Pharmaceutical's Net Current Asset Value has ranged from 5.12 to 116.98. According to the industry distribution chart, Ultragenyx Pharmaceutical ranks #999999 out of 942 companies in the Biotechnology industry.
Is Ultragenyx Pharmaceutical's Net Current Asset Value too high?
Ultragenyx Pharmaceutical's current Net Current Asset Value is MXN-160.49. Over the past 10 years, this metric has ranged from a low of 5.12 to a high of 116.98. Based on the distribution chart, Ultragenyx Pharmaceutical ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's Net Current Asset Value compare to VERA and IRON?
According to the Biotechnology industry distribution chart, Ultragenyx Pharmaceutical ranks #999999 out of 942 companies for Net Current Asset Value. This places Ultragenyx Pharmaceutical in the lower half of its industry. The industry median Net Current Asset Value is 4.91. Historically, Ultragenyx Pharmaceutical's own Net Current Asset Value has ranged from 5.12 to 116.98 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.91, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Ultragenyx Pharmaceutical and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ultragenyx Pharmaceutical's current Net Current Asset Value is MXN-160.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Ultragenyx Pharmaceutical (MEX:RARE) has a current Net Current Asset Value of MXN-160.49. The stock's GF Value™ is MXN1,699.44, compared to a current price of MXN1,150.56 — trading 32.3% below its estimated fair value. The current Net Current Asset Value is MXN-160.49. Ultragenyx Pharmaceutical's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (MEX:RARE), the current Net Current Asset Value is MXN-160.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ultragenyx Pharmaceutical (MEX:RARE) Overvalued in 2026?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued.
The current stock price of MXN1,150.56 is trading 32.3% below its estimated GF Value™ of MXN1,699.44.
Key valuation signals for MEX:RARE:
Net Current Asset Value: MXN-160.49
GF Value™: MXN1,699.44 vs. price of MXN1,150.56 (32.3% below fair value)
No single metric tells the full story. See the MEX:RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
66GF Score
Get the complete analysis for MEX:RARE
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RARE has been successfully added to your 
